Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

NCT05061017 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

NSCLC
Metastatic Colorectal Carcinoma
Refractory Melanoma

Interventions

DRUG: Pixatimod
DRUG: Nivolumab
DRUG: Cyclophosphamide (low dose)

Sponsor

Diwakar Davar

Collaborators

[object Object]